Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
NCT01094717 · University of Utah · NA · terminated · last registry update 2019-06-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “lack of efficacy and lack of funding” | – | Registry record, University of Utah |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RXRB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-03-04Also stopped (withdrawn): Ottawa Hospital Research Institute, Acitretin (NCT03753867)
- 2020-01-21Results posted on the registry: M.D. Anderson Cancer Center, Bexarotene + Erlotinib (NCT00411632)
- 2019-11-12Results posted on the registry: Bausch Health Americas, Inc., Bexarotene (NCT01007448)
- 2019-03-06Results posted on the registry: Dartmouth-Hitchcock Medical Center, Bexarotene (targretin) + Bexarotene (targretin) (NCT00153842)
- 2019-03-06Also stopped (terminated): Dartmouth-Hitchcock Medical Center, Bexarotene (targretin) + Bexarotene (targretin) (NCT00153842)
- 2018-12-26Also stopped (terminated): University of Arizona, Acitretin + Vemurafenib (NCT02050321)
- 2018-11-13Results posted on the registry: Konstantin Dragnev, erlotinib and bexarotene (NCT00125359)
- 2018-11-13Results posted on the registry: Dartmouth-Hitchcock Medical Center, erlotinib (Tarceva) and bexarotene (Targretin) (NCT00125372)
- 2018-10-18Also stopped (terminated): University of Washington, vorinostat (NCT00958074)
- 2018-09-05Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, sargramostim + bexarotene (NCT00425477)
- 2018-08-16Results posted on the registry: Memorial Sloan Kettering Cancer Center, Targretin® (bexarotene) + pegylated liposomal doxorubicin hydrochloride (NCT00255801)
- 2018-07-19Also stopped (withdrawn): Günther Hofbauer, Chemopreventive application (Acitretin) (NCT00488384)
- 2018-07-09Also stopped (terminated): European Organisation for Research and Treatment of Cancer - EORTC, bexarotene + methoxypsoralen (NCT00056056)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision